Related Experiment Videos
Bone marrow transplantation for myeloblastoma
K Quabeck1, D W Beelen, H K Mahmoud
1Innere Klinik und Poliklinik (Tumorforschung), Universitätsklinikum der GHS Essen, F.R.G.
European Journal of Haematology
|August 1, 1988
Summary
A young man with myeloblastoma achieved remission after chemotherapy, radiation, and surgery. He then underwent a successful allogeneic stem cell transplant, maintaining complete remission with controlled graft-versus-host disease.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Myeloblastoma is a rare tumor that can present as bulky mediastinal and retroperitoneal masses.
- Aggressive multimodal therapy is often required for treatment.
- Allogeneic stem cell transplantation (SCT) is a potential treatment option for refractory or relapsed cases.
Observation:
- A 20-year-old male presented with extensive myeloblastoma.
- Initial treatment included chemotherapy, mediastinal irradiation, and retroperitoneal tumor resection, achieving partial remission.
Findings:
- The patient underwent allogeneic SCT from an HLA-identical sibling, utilizing a conditioning regimen of high-dose busulfan and cyclophosphamide.
- Post-transplant, the patient developed and has a well-controlled secondary chronic graft-versus-host disease.
- At 20 months post-transplantation, the patient remains in unmaintained complete remission and is in good general health.
Implications:
- This case highlights the potential efficacy of allogeneic SCT in managing advanced myeloblastoma.
- Successful engraftment and sustained remission suggest SCT can be a viable consolidation strategy.
- Long-term monitoring for graft-versus-host disease and disease recurrence is crucial.